Transforming Revision Surgery.

Explore Our Solution

Revision surgeries are rising, and so are the risks.

As more joint replacements are performed globally, failures are increasing. By 2030, over 500,000 patients annually will need complex orthopaedic revision surgery. Yet many of these cases involve cemented implants, making them more difficult, risky, and expensive to treat.

The Problem

Bone cement removal is the most difficult part of orthopaedic revision. It can add up to 60 minutes to surgery time, increasing costs, risks, and surgeon fatigue — all while worsening patient outcomes.

Longer surgeries Higher costs Worse outcomes Surgeon fatigue

Why It Matters

In the UK alone, 2.8 million people are economically inactive due to long-term health conditions. Musculoskeletal issues are the second leading cause, affecting 646,000 people — placing a growing burden on healthcare services and society.

2.1M Major joint revision procedures each year
£17.5B+ Global joint replacement market
50% Of implants are cemented — hard to remove
6–10% Of implants fail, requiring complex revision
Transforming Revision Surgery

Transforming Revision Surgery

We develop patient-specific solutions that set new standards in orthopaedic revision, empowering surgeons to operate with greater accuracy and confidence.

Precision for Better Outcomes

Precision for Better Outcomes

Our innovative approach reduces surgical time, improves bone preservation, and enhances patient recovery — delivering measurable improvements in care.

Trusted by Surgeons & Expert Design Engineers

Trusted by Surgeons & Expert Design Engineers

Built on clinical expertise and rigorous engineering, our solutions are designed in collaboration with leading surgeons and research institutions worldwide.

Key Metrics & Milestones

Funding
£1.6M+ in secured funding to date, supporting robust R&D and early-stage growth.
Patient-Specific
100% patient-specific planning — no standardised, one-size-fits-all approach.
3-Year Roadmap
Scaling from pilot to clinical adoption through R&D, product launches, and partnerships.
£2B+
UK, EU & USA Revision Market
NHS EU UK
2 Patents Filed 1 Patent Granted (EU)

Market Opportunity & Early Traction

3 major NHS trusts are piloting Amotio’s technology. Our IP is protected by two filings (one granted). The UK, EU & USA market alone exceeds £2 billion annually, and our clinical advisory board includes leading surgeons and regulatory experts.

Investor Relations

Follow Us on LinkedIn

Stay up to date with our latest company news, events, and insights into the future of orthopaedic revision surgery.

Our Partners & Affiliations

Backed by trusted institutions in health innovation and investment.

NLC ORUK Utrecht Holdings
Innovate UK Welsh Gov
Torfaen MediWales

Ready to Shape the Future of Orthopaedic Care?

Join our mission to make advanced revision surgery safer, faster, and accessible to every patient. Connect now to review pilot results, explore partnership, or invest in Amotio’s next chapter.